SEC Form 4 · accession 0001209191-18-012430
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Errol B Desouza
Director
Period of report
Feb 20, 2018
Accepted (ET)
Feb 22, 2018 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Redeemable Convertible NoteF1,F3,F4 | $137.85 | Feb 20, 2018 | J | — | D | — | — | Common Stock | 78 | — | D |
| Redeemable Convertible NoteF1,F3,F4 | $137.85 | Feb 20, 2018 | J | 4,679 | D | — | — | Common Stock | 33 | 0 | D |
Explanation of responses
- F1Reflects a 1:15 reverse stock split effected on February 10, 2017.
- F2Reflects a redeemable convertible note of the Issuer (the "Note") that matured, with the face value of the Note repaid to the Reporting Person.
- F3At the option of the Reporting Person, at any time on or before February 19, 2018, the Note was redeemable into cash at a rate of $1 for each $1 principal amount of the Note or convertible into shares of common stock of the Issuer at a conversion rate of $137.85 per share, respectively.
- F4The Note matured on February 19, 2018.